Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

141.54 +0.08 (+0.06%)

Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

53 54 Next >

Novartis Ag (NVS) Q2 2023 Earnings Call Transcript ↗

July 18, 2023

NVS earnings call for the period ending June 30, 2023.

Via The Motley Fool

NBCUniversal's Peacock Raises Prices First Time Since Launch, Warren Buffett Sells Majority of Activision Blizzard Stake Before Microsoft Deal Approval, Novartis Launches $15B Share Buyback: Today's Top Stories ↗

July 18, 2023

Wall Street Journal

Via Benzinga

Novartis Puts Up Its Biggest Earnings Growth In Two Years; Shares Pop ↗

July 18, 2023

Novartis put up more than 17.3% growth in its profit, beating quarterly records since June 2021.

Via Investor's Business Daily

Novartis Q2 Earnings: Company Lifts Outlook, Launches $15B Share Buyback, Maps Out Sandoz Spin-Off ↗

July 18, 2023

Novartis AG (NYSE: NVS) reported Q2 FY23 sales of $13.62 billion, up 7% Y/Y and 9% on constant currency, beating the consensus

Via Benzinga

Nasdaq, S&P 500 Futures Dip Ahead of Big Bank Earnings, Retail Sales Data: Why This Analyst Stays Cautious About Tech Sector ↗

July 18, 2023

Via Benzinga

Earnings Preview For Novartis ↗

July 17, 2023

Via Benzinga

Expert Opinions on Dry Eye Treatment Innovations

July 13, 2023

CRANBURY, N.J. - July 13, 2023 - PRLog -- IVIEW Therapeutics Inc. a clinical stage biotechnology company focusing on developing innovative ophthalmic therapeutics, organized a panel of dry eye experts...

Via PRLog

(NVS) - Analyzing Novartis's Short Interest ↗

July 12, 2023

Via Benzinga

Bank of America, Morgan Stanley And 3 Stocks To Watch Heading Into Tuesday ↗

July 18, 2023

With U.S. stock futures trading slightly lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:

Via Benzinga

Drug Maker Novartis Stock Shows Rising Relative Strength ↗

July 17, 2023

Novartis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the preferred 80-plus score.

Via Investor's Business Daily

MoonLake's Potential Sale: Stock Price Up Fivefold Since Public Debut In 2022 ↗

July 17, 2023

MoonLake Immunotherapeutics (NASDAQ: MLTX) has reportedly engaged an investment bank as the Swiss company looks for a potential sale. The company focuses on developing antibody-derived treatments for...

Via Benzinga

The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market ↗

July 17, 2023

The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.62% from 2023 to 2030.

Via Benzinga

S&P Makes Weekly Advance As Inflation Reaches Lowest Level Since March 2021; Amazon, Microsoft, Alphabet And Major Banks Lead Market Optimism ↗

July 14, 2023

The S&P 500 is closing the week in the green in light of positive inflation data. The index was 2.48% higher on the week ahead of the market close Friday. Other major market indexes also showed an...

Via Benzinga

Eli Lilly Unveils A Nearly $2 Billion Deal To Leap Ahead In Weight Loss ↗

July 14, 2023

The company is hoping to curb the lean muscle mass loss tied to weight-loss drugs.

Via Investor's Business Daily

The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly? ↗

July 13, 2023

An overweight world is hungry for new treatments. For now, two companies own the market.

Via Investor's Business Daily

3 Penny Stocks to Catapult You Into the Millionaires’ Club ↗

July 13, 2023

These penny stocks can deliver tremendous upside from their depressed range. Wall Street analysts can back it up!

Via InvestorPlace

Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus

July 13, 2023

Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth.

Via MarketBeat

Topics Retirement

A Comprehensive Study Exploring Viral Disease Diagnosis Market : Key Players BioMerieux, Prescient Medicine Holdings, Danaher

July 12, 2023

AMA released Viral Disease Diagnosis Market research study .Check what differences transitions in customer choices may bring?

Via SBWire

Why Are BeiGene Shares Trading Lower Today ↗

July 11, 2023

BeiGene Limited (NASDAQ: BGNE) shares are trading lower after the company mutually agreed to

Via Benzinga

Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ: WINT) Is Helping Change That ↗

July 12, 2023

Windtree Therapeutics, Inc. (NASDAQ: WINT), a biotechnology company treating late-stage acute cardiovascular disorders, is advancing its first-in-class drug for serious heart conditions.

Via Benzinga

3 Biotech Stocks That AI is Loving in July ↗

July 12, 2023

As AI becomes a more entrenched aspect of society, investors can lean on these AI recommended biotech stocks with predicted high potential.

Via InvestorPlace

US Court Issues Negative Decision On Novartis' Heart-Failure Drug Patent ↗

July 10, 2023

Swiss pharma giant Novartis AG (NYSE: NVS)

Via Benzinga

Why Novartis Stock Slipped on Friday ↗

July 07, 2023

A major company product lost a key legal protection.

Via The Motley Fool

Bausch + Lomb Expands OTC Eye Care Portfolio, Acquires JNJ's Blink ↗

July 06, 2023

Bausch + Lomb Corporation (NYSE: BLCO) has acquired Johnson & Johnson's (NYSE: JNJ) eye and contact lens drops brand Blink for $106.5 million to bolster its position in over-the-counter (OTC)...

Via Benzinga

Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire ↗

July 05, 2023

Chinook Therapeutics has a history of being opportunistic. Now, it's joining forces with Novartis.

Via Investor's Business Daily

#blackartmatters Series And Inaugural Talk By Gallerist Lewis P. Long

July 06, 2023

Famed Harlem gallery owner, Lewis P. Long, is set to lead the first talk of #BlackArtMatters, sponsored by Morristown's revered Art in the Atrium.MORRISTOWN, N.J. - July 6, 2023 - PRLog -- Famed Harlem...

Via PRLog

Novartis Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

July 06, 2023

Via Benzinga

Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment ↗

July 03, 2023

Biogen Inc (NASDAQ: BIIB) announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting

Via Benzinga

Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront ↗

July 01, 2023

Via Talk Markets

Generalized Myasthenia Gravis Market expected to rise | Companies- Biocon, Cartesian Therapeutics, UCB, Momenta Pharamaceuticals, HanAll Biopharma, Roche, Alexion, Novartis, Takeda, BioMarin

June 30, 2023

Via AB Newswire

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

53 54 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today